{"url_path":"/sec/chrs/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1512762/0001104659-26-058703-index.html","accession_number":"0001104659-26-058703","cik":"0001512762","ticker":"CHRS","issuer_name":"Coherus Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1512762/0001104659-26-058703-index.html","primary_entity_key":"0001512762","primary_entity_name":"Coherus Oncology, Inc."},"word_count":691,"has_tables":true,"body_markdown":"**ITEM  6.             Exhibits**\n\n​\n\nReference is made to the Index to Exhibits included in this Quarterly Report on Form 10-Q.\n\nINDEX TO EXHIBITS\n\n​\n\n​\n\n​\n\n​\n\n**Incorporated by Reference**\n\n​\n\n​\n\n**Exhibit**\n**Number**\n\n  ​ ​ ​\n\n**Description**\n\n  ​ ​ ​\n\n**Form**\n\n  ​ ​ ​\n\n**Exhibit**\n\n  ​ ​ ​\n\n**Date**\n**Filed**\n\n  ​ ​ ​\n\n**Filed**\n**Herewith**\n\n3.1\n\n​\n\n[Amended and Restated Certificate of Incorporation.](https://www.sec.gov/Archives/edgar/data/1512762/000119312514409798/d820280dex31.htm)\n\n​\n\n8-K\n\n​\n\n3.1\n\n​\n\n11/13/2014\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.2\n\n​\n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Coherus BioSciences, Inc. (the previous name of Coherus Oncology, Inc.), effective as of May 29, 2025](https://www.sec.gov/Archives/edgar/data/1512762/000155837025008294/chrs-20250529xex3d1.htm)\n\n​\n\n8-K\n\n​\n\n3.1\n\n​\n\n5/30/2025\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.3\n\n​\n\n[Second Amended and Restated Bylaws of Coherus Oncology, Inc., effective as of May 29, 2025.](https://www.sec.gov/Archives/edgar/data/1512762/000155837025008294/chrs-20250529xex3d2.htm)\n\n​\n\n8-K\n\n​\n\n3.2\n\n​\n\n5/30/2025\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n4.1\n\n​\n\nReference is made to exhibits 3.1, 3.2 and 3.3.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n4.2\n\n​\n\n[Form of Common Stock Certificate.](https://www.sec.gov/Archives/edgar/data/1512762/000119312514380821/d744283dex42.htm)\n\n​\n\nS-1/A\n\n​\n\n4.2\n\n​\n\n10/24/2014\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n4.3\n\n​\n\n[Indenture, dated as of April 17, 2020, between Coherus Biosciences, Inc. and U.S. Bank National Association, as Trustee.](https://www.sec.gov/Archives/edgar/data/1512762/000110465920048214/tm2015668d4_ex4-1.htm)\n\n​\n\n8-K\n\n​\n\n4.1\n\n​\n\n4/17/2020\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n4.4\n\n​\n\n[Form of certificate representing the 1.5% Convertible Senior Subordinated Notes due 2026.](https://www.sec.gov/Archives/edgar/data/1512762/000110465920048214/tm2015668d4_ex4-1.htm)\n\n​\n\n8-K\n\n​\n\n4.1\n\n​\n\n4/17/2020\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n4.5\n\n​\n\n[Notice of Successor Trustee to Indenture dated February 7, 2022.](https://www.sec.gov/Archives/edgar/data/1512762/000155837022007420/chrs-20220331xex4d5.htm)\n\n​\n\n10-Q\n\n​\n\n4.5\n\n​\n\n5/5/2022\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n4.6\n\n​\n\n[First Supplemental Indenture, dated March 31, 2025, between Coherus BioSciences, Inc. and U.S. Bank Trust Company, National Association, as trustee.](https://www.sec.gov/Archives/edgar/data/1512762/000155837025004264/chrs-20250331xex4d1.htm)\n\n​\n\n8-K\n\n​\n\n4.1\n\n​\n\n4/1/2025\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n31.1\n\n​\n\n[Certification of Principal Executive Officer Required under Securities Exchange Act Rule 13a-14(a) and 15d-14(a).](chrs-20260331xex31d1.htm)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nX\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n31.2\n\n​\n\n[Certification of Principal Financial Officer under Securities Exchange Act Rule 13a-14(a) and 15d-14(a).](chrs-20260331xex31d2.htm)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nX\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n32.1\n\n​\n\n[Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350 and Securities Exchange Act Rule 13a-14(b).](chrs-20260331xex32d1.htm)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nX\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n101\n\n​\n\nThe following materials from Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 formatted in iXBRL (Inline eXtensible Business Reporting Language) includes: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) Condensed Consolidated Statements of Stockholders’ Equity (Deficit), (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Condensed Consolidated Financial Statements.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nX\n\n104\n\n​\n\nCover page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101).\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nX\n\n​\n\n​\n\n​\n\n​\n\n84\n\n[Table of Contents](#TOC)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n​\n\n  ​ ​ ​\n\n**COHERUS ONCOLOGY, INC.**\n\n​\n\n​\n\n​\n\nDate: May 11, 2026\n\n​\n\n/s/ Dennis M. Lanfear\n\n​\n\n​\n\nDennis M. Lanfear\n\n​\n\n​\n\nPresident and Chief Executive Officer\n\n​\n\n​\n\n(Principal Executive Officer)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nDate: May 11, 2026\n\n​\n\n/s/ Bryan McMichael \n\n​\n\n​\n\nBryan McMichael\n\n​\n\n​\n\nChief Financial Officer\n\n​\n\n​\n\n(Principal Financial Officer and Principal Accounting Officer)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n85"}